Further increased YAP nuclear localization has also been reported to be associated with chemotherapy resistance and relapse in EGFR-mutant, KRAS-mutant and B-RRAF mutant, ALK-rearranged non-small-cell lung cancer and RAS-driven neuroblastoma (19, 22, 45–51). This evidence concerns the gene KRAS and non-small cell lung carcinoma.